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BACKGROUND: Breast microcalcifications are key diagnostically significant radiological features for localisation of malignancy. This study
explores the hypothesis that breast calcification composition is directly related to the local tissue pathological state.
METHODS: A total of 236 human breast calcifications from 110 patients were analysed by mid-Fouries transform infrared (FTIR)
spectroscopy from three different pathology types (112 invasive carcinoma (IC), 64 in-situ carcinomas and 60 benign). The
biochemical composition and the incorporation of carbonate into the hydroxyapatite lattice of the microcalcifications were studied by
infrared microspectroscopy. This allowed the spectrally identified composition to be directly correlated with the histopathology
grading of the surrounding tissue.
RESULTS: The carbonate content of breast microcalcifications was shown to significantly decrease when progressing from benign to
malignant disease. In this study, we report significant correlations (Po0.001) between microcalcification chemical composition
(carbonate content and protein matrix:mineral ratios) and distinct pathology grades (benign, in-situ carcinoma and ICs). Furthermore,
a significant correlation (Po0.001) was observed between carbonate concentrations and carcinoma in-situ sub-grades. Using the two
measures of pathology-specific calcification composition (carbonate content and protein matrix:mineral ratios) as the inputs to a
two-metric discriminant model sensitivities of 79, 84 and 90% and specificities of 98, 82 and 96% were achieved for benign, ductal
carcinoma in situ and invasive malignancies, respectively.
CONCLUSIONS: We present the first demonstration of a direct link between the chemical nature of microcalcifications and the grade of
the pathological breast disease. This suggests that microcalcifications have a significant association with cancer progression, and could
be used for future objective analytical classification of breast pathology. A simple two-metric model has been demonstrated, more
complex spectral analysis may yeild greater discrimination performance. Furthermore there appears to be a sequential progression
of calcification composition.
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In the UK incidence rates of breast cancer have increased by 50%
over the last 25 years to around 44000 women and 300 men per
annum (DH, 2005). Mammography is used routinely as a method to
screen populations for breast cancers, however, only around 10–25%
of mammographically suspicious lesions are found to be malignant
from tissue biopsy (Evans et al, 1999), resulting in unnecessary and
costly biopsy procedures. In 2004/05 in the UK 1749185 women were
screened, of which 85710 (4.9%) women had further tests and only
13993 (0.8%) were found to have malignancies present (Evans et al,
1999; DH, 2005). This demonstrates that in the UK alone, 71717
women in 2004/05 had further investigations, including excisional
biopsy, with all the associated risks, costs and anxiety involved, when
they had no malignancies present.
Breast tissue microcalcifications observed radiologically are
frequently employed as a marker for breast pathology type as they
can act as a strong differentiator between benign and proliferative
(type I and type II, respectively) breast lesions and as an indicator
of the presence of an early breast cancer. It is often the presence of
type II calcification on mammography that leads to further
investigations. However, to date it has not been possible to clearly
distinguish between the proliferative lesions on the basis of the
presence of type II calcium hydroxyapatite. Around 86% of
mammograms have been shown to contain visible microcalcifica-
tions in women aged 76–79 years (DH, 2005). Survival of patients
with mammographic microcalcifications is significantly shorter
than those without (Ketcham and Muffat, 1990; Holme et al, 1993)
and a significantly larger number of lymph nodes are involved in
patients with tumours showing microcalcifications than those
without (Holme et al, 1993).
Furthermore, as the introduction of mammographic screening
in the UK, the incidence of ductal carcinoma in situ (DCIS)
has increased from 2 to 20% of all cancers presenting (Office
for National Statistics: registrations, 2000), with 80% of DCIS being
detected because of the microcalcifications in the mammogram.
It has been shown that 50% of patients with microscopic
foci of DCIS develop invasive carcinoma (IC) (Page et al, 1982),
and that progression to invasion is related to grade. The most
advanced form of DCIS: comedo disease, progresses into IC
both more often and more rapidly than low grade DCIS (Office
for National Statistics: registrations, 2000). However, there is
no clear consensus among pathologists (over six different
classification systems)—there remain major discrepancies in DCIS
grading.
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changes in tissue morphology, but generally do not identify the
underlying biochemical changes that distinguish benign from
malignant tissue.
Microcalcifications
Microcalcifications are divided into type I (calcium oxalate) and
type II (carbonated calcium hydroxyapatite—CHAP). Type I are
mainly associated with benign breast disease. However, type II are
the most frequently observed calcifications (Haka et al, 2002), and
can be found in both benign and malignant proliferative lesions,
although they are mostly found to be associated with malignancy.
Apatite calcification in other biological tissues is generally
composed of calcium-deficient, carbonated hydroxyapatite
(Pleshko et al, 1991) with most of the carbonate ions substituting
at the phosphate site up to 5–6wt% phosphate. The carbonate
substitution within such bioapatites has the effect of significantly
increasing the minerals’ chemical reactivity (Nelson, 1981).
Differences have previously been found in the biochemical
composition of type II microcalcifications occurring in benign and
malignant tissue (Haka et al, 2002). It was found from Raman
spectroscopic analysis of breast microcalcifications that carbonate
content is greater in type II (CHAP) calcifications from benign
than malignant breast tissue. However, beyond this, there remains
very little chemical information concerning these microcalcifica-
tions. It would, therefore, be of great value to investigate further
the biochemical nature of these type II microcalcifications and
to determine whether particular features are characteristic of
different pathology types and sub-grades.
The study outlined here aims to determine the carbonate content
and the amount of CHAP mineral in comparison to tissue matrix, in
type II microcalcifications, in three distinct pathology types (benign,
in-situ and invasive) and also between invasive cancer grades
(grades 1, 2 and 3) and stages of DCIS (low, intermediate and high
grade (HG)). The association of calcification chemistry with
increasing histological grade of tissue will also be examined.
The combination of relative carbonate content with other
parameters of a biochemical nature would be of great value in
diagnosis, allowing the possibility of differentiation of tissue
pathology on the basis of the direct analysis of CHAP spectra. The
combination of spectral acquisition with microscopy, would allow
direct comparison of biochemical information with histology,
possibly leading to a more accurate diagnosis. Furthermore, there
are advancing forms of Raman spectroscopy that would allow this
information to be obtained non-invasively using low power laser
light (Haka et al, 2002; Crow et al, 2005). Measurement of
calcification spectra from a depth within mammalian and human
breast tissues has already been shown to be possible (Baker et al,
2007; Stone et al, 2007a,b). Recent advances have demonstrated
that composition could be elucidated through 27mm of porcine
tissue (Stone and Matousek, 2008), with further developments
expected (Stone and Matousek, 2008) to make this possible for
breast thicknesses of 3–5cm.
METHODS
Specimens
Breast tissue specimens were collected from 110 patients
of different pathology types (21 benign, 31 in-situ carcinoma
(low–high grade) and 56 invasive-grades 1–3). Out of these 110
specimens, 106 (21 benign, 30 in-situ and 55 invasive cancer) were
analysed by FTIR spectroscopy, as no calcifications could be
found in the others. Altogether, 236 calcifications were analysed
(60 benign, 64 in-situ and 112 invasive). The specimens were
selected from examination of radiographs from archives of
patients who had undergone biopsy for mammographically
suspicious breast lesions at Gloucestershire Royal Hospital
between 1996 and 2007 (ethical approval Gloucestershire Local
Research Ehics Committee). Samples that were known, from
histopathology reports, to contain calcifications were chosen. The
paraffin-set biopsy blocks were then retrieved from storage,
microtomed to 7-mm thickness and mounted onto calcium fluoride
(CaF2) slides for FTIR analysis. The Nottingham grading system
was used (Ellis et al, 2005) to define the pathologies of the tissues
surrounding the calcifications in this study. This is the system used
for routine breast pathology in Gloucestershire Hospitals, UK.
Invasive samples included invasive ductal and invasive lobular
carcinoma (ILC) of varying grades between 1 (least aggressive) and
3 (most aggressive). In-situ samples ranged from ductal carcinoma
to lobular carcinoma of high, intermediate and low grades.
Benign samples included atypical ductal hyperplasia, usual type
hyperplasia, fibroadenoma, fibrocystic change, papillary lesions,
periductal elastosis, duct ectasia and sclerosing adenosis.
It should be noted that two benign calcifications came from
samples also exhibiting DCIS (intermediate grade); four DCIS
calcifications were from the tissue containing both low and HG; the
five lobular carcinomas in situ were found in mixed samples
with DCIS; one sample contained both ILC and invasive ductal
carcinoma (IDC). Otherwise samples were classified as pathologi-
cally homogeneous.
Experimental
FTIR instrumentation Samples were measured by Fourier
transform mid-infrared (mid-FTIR) microspectroscopy using a
Perkin Elmer Spotlight 300 system (Seer Green, Buckinghamshire,
UK), incorporating a 16 1 element (400 25mm) mercury–
cadmium–telluride array detector and a single point, 100 100mm
mercury–cadmium–telluride detector. Both detectors were liquid-
nitrogen cooled. The detectors are sensitive over the spectral range
from 720 to 4000cm
 1, which is equivalent to wavelengths of
around 14 and 2.5mm, respectively. Visible images were collected
under white light LED illumination by a Charge Coupled Device
camera, which allowed selection of regions for imaging.
Mapping/point measurements of paraffin-embedded specimens Tis-
sue sections containing calcifications, and the locally surrounding
tissue were imaged using a pixel size of 6.25mm and a 4cm
 1
spectral resolution with 64 scans per pixel. One or two image maps
were taken per sample, containing a total of 236 calcifications and
averaging around 7000 spectra per map. A mean spectrum was
then taken of the areas of calcification from the spectral image
map, and used for calculation of amide: phosphate ratios and for
partial least square calculation of carbonate content (see Figure 1).
Point measurements of CHAP standards for partial least square
model construction The CHAP standards were obtained
(Clarkson Chromatography Products, South Williamsport, PA,
USA) in powder form, sprinkled finely onto CaF2 slides and
measured in transmission mode. Point spectra of CHAP standards
containing pure hydroxyapatite and CHAP of 0.5, 1.4, 2.3 and 3.5%
carbonate incorporation, were collected on the FTIR system.
Spectra were taken from 10 areas on each CHAP/HAP sample.
Each spectrum was acquired with 64 scans and a 4cm
 1 resolution,
with a spectral range of 720–4000cm
 1. Background scans were
obtained from a blank section of the CaF2 slide and a ratio was
obtained against the sample spectrum each time. The average
spectrum from each standard is shown in Figure 2. As the
carbonate substitution increased (from 0 to 3.5%), the spectra
showed an increasing intensity (compared with that of the
baseline) of all carbonate peaks, most easily seen by looking at
the doublets appearing at around 1410 and 1450cm
 1.
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squares prediction model was constructed, which enabled calcula-
tion of the amount of carbonate present in unknown samples by
analysis of their spectral patterns. Initially, the spectra were
truncated to 750–2000cm
 1 and converted to second derivative
spectra, which have been shown to be optimal for many FTIR
spectral analysis models (Paschalis et al, 1996; Gao et al, 1999;
Beleites et al, 2005; Das et al, 2007). The partial least square model
was constructed with four latent variables from the 49 CHAP
spectra, which described over 93% of the data, without including
other factors that may result in over-fitting. A standard error of the
mean was calculated as ±0.17% (CO3
2  substitution). Figure 3
shows the predictive value of the model when tested using leave-
one-out cross-validation.
RESULTS
Figure 4 displays the measured increase in the carbonate
composition of the breast calcifications from invasive through to
benign breast tissue. When the groups are combined into the three
key groups of invasive, in situ and benign disease mean carbonate
values were found to be 1.41, 1.83 and 2.08%, respectively. These
differences were greater than 99.9% signficiant with P-values
calculated from Student’s t-tests of the data of 5 10
 40 (invasive
vs benign), 1 10
 21 (invasive vs in-situ) and 3 10
 20 (in-situ vs
benign).
The carbonate content was also compared for grades of invasive
cancer (invasive ductal carcinoma and ILC) ranging from grade 1
(least invasive) to grade 3 (most invasive) and grades of ductal
carcinoma in-situ (DCIS) (see Figure 5). A decrease in carbonate
content was seen from low- to high-grade DCIS and from grades
1–3 of invasive cancer. Population testing showed that the
carbonate values associated with each invasive cancer grade
were significantly different (Po0.001). The carbonate content
was not significantly different between low and intermediate grade
DCIS calcifications, although it was (Po0.001) significant between
low and HGs and intermediate and high-grades of DCIS.
An increase in the matrix:mineral (amide:phosphate) ratio
was seen in calcifications from increasingly malignant tissue.
Significant differences were observed between benign, in-situ and
invasive tissue types, when grouped together, see Figure 6
(Po0.001). No significant differences in amide:phosphate ratio
was observed between invasive cancer grades or between DCIS
grades (P40.001).
By using the two parameters outlined above, each calcification
measured could be marked on a scatter plot by the relative level
of carbonate concentration and amide:phosphate ratio. This is
shown in Figure 7. The plot demonstrates the clustering of
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Figure 1 (A) An example of how mean regions were selected, showing a false colour image of PC score 3 of an invasive cancer sample with selected
regions indicated by red boxes. (B) Average spectra of those collected from area within red box in (A). Absorbance peaks corresponding to vibrational
modes from the phosphate (around 1020cm
 1) and amide I (1650cm
 1) are indicated by arrows.
1023–1028 05 CHAP
14 CHAP
961
1093
1110
23 CHAP
35 CHAP
CHAP
873
861
878
1414
1453
1548
I
n
t
e
n
s
i
t
y
800 1000 1200 1400 1600 1800 2000
0.8
0.9
0.4
0.5
0.6
0.7
0.1
0.2
0.3
–0.1
0
Wavenumber (cm–1)
Figure 2 Mean spectrum from each CHAP standard ranging from 0 to
3.5% carbonate substitution.
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Figure 3 Partial least square model showing actual against predicted
% carbonate content in the 49 measured CHAP spectra.
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samples cover a larger distribution of values than the benign
specimens measured. Furthermore the two metrics could be used
as inputs to a linear discriminant model. Tables 1 and 2 show the
performance of this model for discrimination between the three
key pathologies using the calcification spectra.
An assessment was made of the variation between calcification
composition from breast disease of different origins. Supplemen-
tary Figure S1 demonstrates the difference in these spectral
parameters between IDC and ILC). Only six ILC specimens were
obtained (one containing an additionally diagnosed IDC). All five
containing only ILC appeared to have spectral parameters that lay
within the same range as the IDC calcifications, although all had
amide:phosphate ratios of less than 1%, and carbonate contents
greater than 1%.
The in-situ carcinoma specimens all consisted of DCIS, with five
containing both LCIS and DCIS. The spectral measurement of
carbonate and amide:phosphate ratios from calcifications
for these five samples (Supplementary Figure S2) appeared to lie
within the normal range expected for calcifications from DCIS tissue.
A further examination was made between potentially associated
grades of disease. The carbonate content between high-grade DCIS
and invasive cancer G1 was not significantly different (P¼0.54),
the amide to phosphate ratios were also not statistically significant,
although it came close (P¼0.0014). A P-value of 0.007 was
achieved when testing the difference between carbonate content
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Figure 4 Mean carbonate content in calcifications from invasive, in-situ
and benign breast tissue (mean values are 1.41 for invasive; 1.83 for in-situ
and 2.08 for benign). Error bars show the standard deviation of the values
measured. P-values calculated from Student’s t-tests of the data were
5 10
 40 (invasive vs benign), 1 10
 21 (invasive vs in-situ) and 3 10
 20
(in-situ vs benign) (total number of calcifications¼236).
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Figure 5 Mean carbonate content in calcifications from all invasive, in-situ
and benign breast tissue groups studied. Error bars show the standard
deviation of the values measured.
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Figure 6 Mean amide:phosphate ratios for calcifications from all
pathology groups studied. Mean values for the three groups of invasive,
in-situ and benign breast tissue calcifications were 0.8278, 0.3717 and
0.1114, respectively, P-values calculated from Student’s t-tests of the data
were 2.3 10
 16 (invasive vs benign), 1.5 10
 8 (invasive vs in-situ) and
2.6 10
 15 (in-situ vs benign) (total number of samples¼236).
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Figure 7 Scatter plot showing separation of calcifications from invasive
(n¼112), in-situ (n¼64) and benign (n¼60) pathology groups based on
carbonate content and amide to phosphate ratios.
Table 2 Performance of two-metric disciminant model
Benign DCIS Invasive cancers
Sensitivity per % 79 84 90
Specificity per % 98 82 96
Abbreviation: DCIS¼ductal carcinoma in situ.
Table 1 Confusion matrix of performance of model for each calcification
vs histopathology of the surrounding tissue
Two-metric prediction
Benign DCIS Invasive cancers
Histopathology
Benign 88 24 0
DCIS 3 54 7
Invasive cancers 0 6 53
Abbreviation: DCIS¼ductal carcinoma in situ.
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difference between moderate-grade DCIS and IC G2 and high-
grade DCIS and IC G3 were once again highly significant with
P-values o10
 10.
DISCUSSION
Significant differences in carbonate content between the micro-
calcifications of benign, in-situ and invasive breast tissues were
observed. Furthermore, significant differences were also demon-
strated between invasive cancer grades (G1-3) and for ductal
carcinoma in-situ (DCIS) between high- (HG) and low-grade and
HG and intermediate grade. A key finding was that a decrease in
carbonate content followed a continuum from benign to increas-
ingly malignant tissue.
Differences were greater between the invasive cancer grades
than between the DCIS grades, indicating that as the tissue
increases in malignancy, the carbonate content within correspond-
ing calcifications decreases at a greater rate. There was less of a
decrease in carbonate substitution between increasing DCIS grades
and DCIS HG and IDC G1 were similar in their carbonate content,
suggesting the calcification in high-grade DCIS is in a chemical
state similar to that found within early invasive disease. This
indicates that at least in terms of calcification formation and tissue
physiology these groups are very similar. Therefore, a second key
finding was that the data in this study supports a continuous
pathology model from in-situ and invasive tissues. It must be
noted that molecular biological methods have demonstrated that
there are similarities in cellular molecular expression between
the following pairs of groups of low-grade DCIS and IDC G1 and
high-grade DCIS and IDC G3 (Abdel-Fatah et al, 2008).
The increased carbonate in benign lesion calcifications may be
related to the reactivity of CHAP. Previous studies have shown that
an increase in carbonate within the CHAP lattice directly increases
its reactivity and solubility. The increased concentration of
carbonate results in a less stable structure (Porter et al, 2005)
and upregulated interaction with other ions (Legeros and Legeros,
1993; Miyaji et al, 2005), which may have an inhibitory effect
on its biological activities associated with cancer progression, such
as preventing activation of certain enzymes. For example, it has
been suggested that certain matrix metalloproteases are stimulated
by the presence of CHAP (McCarthy et al, 1992; Reuben et al, 2002;
Sun et al, 2003; Zeng et al, 2003).
Many spectra collected from microcalcifications possessed a
contribution from characteristic soft tissue vibrational modes
of DNA, phospholipids and protein. In particular there was a
noticeable difference in the intensity of the amide I and II peaks
with different pathology type and grade. Perhaps, it is surprising
that the appearance of a tissue ‘matrix’ signal was also seen from
within the centre of many calcifications. Data were collected with
an image pixel size of 6.25mm (and wavelengths of between 5 and
14mm) and a section thickness of 7mm. These dimensions are
significantly smaller than any of the examined calcifications,
therefore, the presence of tissue matrix within the calcification
would be extremely unlikely to be due to measurement of the
surrounding tissue area.
The increase in the matrix:mineral ratio in calcifications in
increasingly malignant tissue appears to be due to an increase in
the amide/protein content, rather than a reduction in the
phosphate content. Invasive tissue generally has an increased
cellular activity and higher protein content (Frank and McCreery,
1995). Our study also supports the findings of Haka (Haka et al,
2002), in which an increase in protein was observed with Raman
spectroscopy in calcifications in invasive compared with benign
tissue. However, it may also be possible that the total mineral
content is greater in calcifications of benign lesions. Benign
calcifications are typically described as being more crystalline,
although this also includes examination of type I (calcium oxalate)
calcifications (Tse et al, 2007). The fact that the nature of
calcifications (carbonate content and matrix:mineral ratios) in
DCIS pathology, appears to lie consistently between benign and
invasive types, indicates that benign tissue calcifications (consist-
ing of fibroadenoma, ductal hyperplasia and fibrocystic change)
are likely to lead to a DCIS, which in turn will result in invasive
disease. Although this appears intuitive it is not a universally
accepted concept. Further insight would be gained by following up
patient disease progression to support the information found when
measuring the archived breast calcification from needle biopsy.
This study has demonstrated that benign, in-situ and invasive
pathologies can be well discriminated using FTIR spectral
measurements to calculate both carbonate content and matrix:-
mineral ratios of calcifications (Figure 7, Tables 1 and 2). This
produces important implications for diagnosis of disease by
calcification measurement using FTIR spectroscopy or other
techniques, such as deep Raman spectroscopy (Stone et al,
2007b, Stone and Matousek, 2008). The determination of these
physio-chemical parameters from invasive tissue calcifications
appeared to be spread over a much larger range and only
minimally overlapped with the in-situ type. There was also a slight
overlap of benign with in-situ, but benign and invasive types were
fully separated, which is an important observation in terms of
diagnosis. This aspect has been further investigated by the use of
linear discriminant analysis prediction models (two-metric model
performance shown in Tables 1 and 2) that can provide a method
of using this data for accurate diagnostic prediction. Further
exploration of multivariate approaches for more accurate dis-
crimination is beyond the scope of this paper.
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